A
Abingworth
Venture CapitalActiveAbingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs.
140
Investments
10
Exits
$2B
AUM
7.1%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Abingworth.
Investment Thesis & Strategy
Abingworth invests in various stages of biotech, health diagnostics, and healthcare companies, partnering with life sciences entrepreneurs to build and grow their businesses.
Investment Activity
Deals per year over the last 19 years
1
20000
20010
20021
20030
20040
20052
20061
20070
20080
20091
20100
20110
20120
20131
20141
20150
20160
20171
2018Portfolio Companies
Selected investments from their portfolio of 140 companies
G
Genmab
Biotech · Series A, 0
M
MorphoSys
Biotech · Series A, 0
I
IONIS Pharmaceuticals
Biotech · Growth, 0
V
Viela Bio
Biotech · Series A, 2018
O
ObsEva
Biotech · Series A, 2015
A
Autolus Therapeutics
Biotech · Series A, 2014
A
Apellis Pharmaceuticals
Biotech · Series A, 2010
C
Catalent
Biotech · Growth, 2007
A
Affimed
Biotech · Series A, 2006
P
Portola Pharmaceuticals
Biotech · Series A, 2006
A
Alnylam Pharmaceuticals
Biotech · Series A, 2003
O
Orexo
Biotech · Series A, 2000
Notable Exits
CompanyTypeYearValue / Acquirer
ObsEvaAcquisition2023—
Kiadis PharmaAcquisition2021$87.5M
Ariad PharmaceuticalsAcquisition2017$5.2B
AlgetaAcquisition2014$2.9B
AffimedIPO2014—
Horizon TherapeuticsIPO2011—
GI DynamicsIPO2011—
OrexoIPO2005—
GenmabIPO2000—
BioMarinIPO1999—
Frequently Asked Questions
Abingworth focuses on Series A, Series B, Series C+ stage investments.